Clinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of the disease, there is a pressing need to identify clinically useful markers of prognosis. Many clinical, pathological, molecular, and genetic factors have been investigated in this capacity, although relatively few are routinely used. With a growing understanding of the molecular pathogenesis of prostate cancer, there is the potential that the next generation of makers will prove sufficiently robust to guide the optimal management of men with prostate cancer. Here, we review the various clinical and molecular prognostic determinants in prostate cancer.
P rostate cancer is a major cause of morbidity and mortality among men in the United States and globally. However, many men with prostate cancer have a slow-growing tumor and experience an indolent course even without curative therapy. 1 The Scandinavian trial of radical prostatectomy versus watchful waiting 2,3 demonstrated that surgery decreases subsequent risk of metastases and prostate cancer death. However, 15 men had to be treated to prevent 1 cancer-specific death during a median 12 years of follow up. Conversely, some men with apparently localized disease die of their cancer despite initial therapy because of the presence of undiagnosed micrometastases.
The biological heterogeneity in prostate cancer has been brought into sharp focus as a result of widespread adoption of prostate-specific antigen (PSA) screening in many countries, with a resulting marked migration toward the diagnosis of lower-risk prostate cancer. 4 There are now more than 240,000 men in the United States diagnosed with prostate cancer each year, 5 and 90% of prostate cancers are clinically localized and occult disease at time of diagnosis. 4 Data from the randomized trials of PSA screening 6Y8 highlight the considerable overdiagnosis and overtreatment of men with screen-detected prostate cancer with very low prostate cancerYspecific mortality rates in modern series. 9 The high incidence of prostate cancer in Western countries underscores the urgency to develop means to distinguish indolent from potentially lethal prostate cancer and accurately identify at the time of diagnosis men for whom treatment is indicated. Traditionally, clinical factors have been used to risk stratify prostate cancer patients and provide guidance around the risk of cancer progression and need for treatment. In the era before PSA screening, these clinical factors provided good, but not perfect, prognostic information. However, the advent of PSA screening has led to a loss in the discriminatory power of these clinical and pathological features. 10 Thus, research has turned to the identification of molecular drivers of prostate cancer, in tumors and circulation, which could be integrated with clinical factors and improve prognostication. The search for molecular prognostic determinants is particularly challenging in prostate cancer, given the enormous intratumoral genomic and biological heterogeneity in most early-stage prostate cancers. Although clinical validation of markers remains limited, several recent additions to the field show great promise.
In this review, we present an overview of evidence on prognostic features in prostate cancer. We discuss clinical and pathological features, as well as molecular markers in tumors and circulation. We also consider some of the major methodological challenges in the identification of prognostic determinants in prostate cancer.
CLINICAL FACTORS
Several clinical and pathological features at the time of diagnosis or surgery have been investigated as potential prognostic factors in prostate cancer. The established tumor-related factors include elevated PSA level at diagnosis, more advanced clinical and pathological tumor stage, higher Gleason score, 10 and positive tumor margins. 9, 11 Kattan et al 12 and others 13, 14 have developed useful nomograms with these parameters to predict biochemical recurrence after prostatectomy. Because of the long clinical course of prostate cancer, especially with the 5-to 10-year lead time added by PSA screening, 15 most studies have used a rise in the PSA following local therapy (biochemical recurrence) to assess the risk of disease progression. This is, however, an imperfect surrogate for prostate cancer mortality, as the vast majority of these men are not destined to die of their disease. 16Y18 
Gleason Grade
Gleason score is the strongest clinical predictor of prostate cancer progression. 19 The grading system, first described in the 1960s, characterizes prostate tumor architecture and morphology. The pathologist assigns a primary and secondary score, and the total score is summed with a range of 2 to 10. Men with tumors of Gleason grade 7 or higher are at increased risk of extraprostatic extension, increased risk of recurrence after initial therapy, and more likely to die of their disease. In contrast, men with a well-differentiated disease of Gleason grade 6 are at very low risk of cancer-specific death. In a multi-institutional radical prostatectomy cohort, the 15-year prostate cancerYspecific mortality rates varied by the age of the patients at diagnosis, ranging from 0.2% to 1% for pathological disease of Gleason 6 or less, 4% to 6% for tumors of Gleason 3+4, 6% to 11% for tumors of Gleason 4+3, and 26% to 37% for tumors of Gleason 8 or higher. 20 The distribution of Gleason grades has shifted over time, 21 and in the era of PSA screening, most men are now diagnosed with Gleason 6 or 7 tumors. As such, the accurate discrimination of prognosis among men with prostate cancer within this narrow range of Gleason scores is challenging. Some, 22 but not all, 23 studies suggest that there is prognostic information among Gleason 7 tumors on whether the predominant pattern is Gleason 4 or 3. For example, in a population-based radical prostatectomy series, men with pathological Gleason 4+3 tumors had a threefold greater risk of prostate cancerYspecific mortality compared with men with Gleason 3+4 tumors. 22 Still, prognostication among Gleason 7 prostate cancer is far from accurate.
An important consideration in evaluating the prognostic value of Gleason has been the noted shift in Gleason grading over time, which has resulted in a general increase in scores with more contemporary reads and almost no men diagnosed with tumors of Gleason grade of less than 6. 21, 24 Moreover, there is considerable interrater variability in assigning Gleason grades across institutions. A comparison of standardized reviews to original Gleason score reviews demonstrates that the systematic upgrading in Gleason results in improved survival for all Gleason categories. 22 
Prostate-Specific Antigen
Both the level of PSA and the velocity of rise before diagnosis have been explored as potential risk factors for poor outcome following definitive treatment. The level of PSA at diagnosis is a component of the standard risk stratification factors 10 and remains a component of most clinical nomograms. 11, 25 With the majority of men diagnosed today through PSA screening, the typical PSA level at diagnosis has decreased, 4 reducing the sensitivity of this measure. A rapidly rising PSA before diagnosis has been identified as a strong predictor for poor outcome following surgery 26 or radiation, 27 although other large studies have not found this relationship among men diagnosed during the PSA era. 9
Perineural Invasion
The presence of cancer cells invading the space around nerves has been found to be of prognostic relevance in other malignancies and is thought to be a mechanism by which prostate cancer can extend beyond the capsule. 28 Numerous studies have investigated the prognostic role of perineural invasion seen on biopsy on outcome following radical local treatment. 29, 30 Observed in between 10% and 40% of cases, the significance of perineural invasion for recurrence has been mixed across studies, although it ultimately appears to be associated with a worsened prognosis. 31 When identified on prostatectomy specimen, this factor has typically not been associated with a worsened outcome. 32 
Clinical Risk Groups and Nomograms
Beyond individual factors, the combination of clinical and pathological factors represents a more powerful tool to aid in prostate cancer prognostication. When combined, the predictive power of the clinical and pathological features has consistently been shown to be greater than any single factor. There are multiple published studies that have developed tools in this regard, including the development of simple risk categories and risk calculators, as well as clinical nomograms. The predictive utility of these combined clinical sets to risk stratify prostate cancer patients has been evaluated primarily in cohorts of patients following curative therapy, either radiation or prostatectomy. Moreover, most have relied on surrogate disease endpoints of PSA recurrence or biochemical failure. We present examples of each type of categorization of features that are used clinically in a variety of settings.
Risk Categories
Risk categories provide clinicians and patients a qualitative assessment of the likelihood of prostate cancer progression after initial therapy. One example of risk categorization is the risk classification of D'Amico et al 10 that divides men into low-risk, intermediate-risk, and high-risk categories of progression after radical prostatectomy, based on clinical stage, biopsy Gleason grade, and preoperative levels of PSA. The risk grouping of an individual patient by the D'Amico classification system is determined by his most clinically advanced clinical feature, rather than a summary consideration of all 3 features. This risk classification system has been demonstrated in independent patient populations to provide accurate prediction of recurrence after radical prostatectomy. 33 
Nomograms
Nomograms are chart-based tools using a scoring system of clinical characteristics to estimate individualized risk of recurrence and progression. The Kattan nomogram 12 is one of the most widely used preoperative nomograms for the prediction of biochemical recurrence after radical prostatectomy. This nomogram uses information on clinical stage, Gleason grade on biopsy, and pretreatment PSA levels to provide predicted probability of biochemical recurrence 5 years after radical prostatectomy. The nomogram was developed in a patient cohort with primarily clinically localized, low-risk disease. A recent study further tested the accuracy of the Kattan nomogram across highand low-risk strata defined by the D'Amico risk classification. 34 In that study, the authors were able to confirm the nomograms' predictive ability to estimate risk of recurrence for patients with high-and low-risk prostate cancer. Prostate-specific antigen recurrence is a good, but not perfect, predictor of development of distant metastases or cancer-specific mortality. Walz et al 25 examined the endpoint of recurrence within 2 years after surgery, given that early recurrence may better reflect the likelihood of micrometastatic disease. This nomogram reported that men with evidence of extraprostatic cancer were much more likely to experience an early recurrence, with a relative risk of early recurrence among men with tumors that had penetrated the capsule of 1.8, and for men with seminal vesicle involvement, a relative risk of 3.
MOLECULAR FACTORS
Although clinical factors have proven useful for risk stratification and guidance of treatment decisions in prostate cancer, significant clinical heterogeneity remains, and many molecular and genetic factors have been explored to better individualize risk prediction. The ideal marker would be measurable at diagnosis, would have both high sensitivity and specificity for distinguishing lethal and indolent prostate cancer, would be cost-effective, and would be reliably measured across observers and institutions. 35 Despite the pressing need to evaluate markers in populations undergoing surveillance, the vast majority of molecular factors have been explored in definitively treated cohorts such as those undergoing radical prostatectomy or radiation therapy. The prognostic value of these markers among potentially untreated men is an area with limited testing. Another important consideration in the evaluation of molecular factors is the selection of disease endpoints. Outcomes have typically focused on recurrence after local therapy as evidenced by a rise in PSA, a feature that does not always correlate to prostate cancer morbidity or mortality.
Notably, unlike other solid tumors, prostate cancer is not characterized by frequent mutations carrying prognostic or predictive value. 36, 37 Thus, molecular factors examined to date in prostate cancer prognostication have focused on alterations in copy number, mRNA, and more recently miRNA. In this review, we highlight molecular tumor features that have been explored as potential biomarkers of prognosis according to the broad hallmarks of cancer described by Hanahan and Weinberg 38, 39 with selected examples provided in Table 1 . Moreover, we discuss the identification of molecular signatures that have been defined from either pathway-based or discovery-based approaches.
Tumor Factors
A variety of tumor-related markers have been investigated as potential prognostic markers in prostate cancer. Early studies were based on small series of clinical cohorts, with insufficient statistical power to detect meaningful associations. More recently, protein expression of immunohistochemical biomarkers has been increasingly utilized and made possible with widespread adoption of tissue microarrays and automated image analysis software for quantification of protein expression. The use of tissue microarrays allows for the study of hundreds of cases while resulting in more uniform and efficient immunohistochemical staining with valid results. Moreover, the application of automated image analysis software has led to high-throughput and quantitative evaluation of biomarkers with highly reproducible results.
Self-Sufficiency in Growth Signals
Unlike normal cells, tumor cells develop the ability to promote growth in the absence of normally regulated signaling systems. There are numerous interrelated, progrowth signaling pathways implicated in prostate cancer progression including androgen signaling, phosphoinositol 3-kinase, epidermal growth factor receptor (EGFR), RAS, and metabolic dysregulation. Studies for each of several pathways of interest are presented in Table 1 as they relate to prognosis.
Insensitivity to Antigrowth Signals
Progression through the cell cycle in normal cells is a wellregulated process involving the interplay of numerous coordinated signaling factors. Loss of these control mechanisms provides tumor cells the opportunity for unchecked growth. In prostate cancer, disruption of several molecular features associated with cell cycle control provides prognostic information following radical prostatectomy including p16/INK4A, p21/ WAF1/CIP1, and p27/KIP1 ( Table 1) . As outlined below, cyclin D1 has also been shown to have prognostic value as a marker. An additional marker thought to be central to antigrowth regulation is the oncogenic transcription factor C-MYC. Increased copy number for MYC is prognostic for worsened outcome in prostate cancer. In addition, the expression of genes related to cell-cycle progression has been associated with poor outcome in a watchful waiting and prostatectomy cohort. 74 
Limitless Replicative Potential
Noncancer cells have a finite capacity to replicate as determined by telomeres. These base-pair repeats at the ends of chromosomes shorten with each cell division, resulting in genome instability when they are no longer capable of protecting the chromosomal ends. 75 Shortened telomere length in tumor cells has been associated with a poor prognosis, although there are relatively few studies investigating this marker in prostate cancer.
Evasion of Apoptosis
Cancer develops in the setting not only of increased progrowth and decreased control signaling but also reduced cell attrition through apoptosis. This well-regulated process of cell death is mediated by a variety of factors, several of which have been explored as prognostic factors in prostate cancer. A central signaling molecule for DNA damage and regulator of apoptosis is p53. The TP53 gene is commonly mutated in other cancers but less frequently in prostate cancer. 36 Nuclear localization of p53, which connotes stabilized mutant protein, has been independently associated with poor prognosis in prostate tumors. Multiple other markers in the apoptotic pathways including BAX and BCL2 have also been explored as prognostic markers in prostate cancer showing potential utility (Table 1) .
Sustained Angiogenesis
As a result of limited diffusion capacity of oxygen and essential nutrients, tumors require the development of new blood vessels as they increase in size in a process referred to as neoangiogenesis. Blood vessels typically form in a highly regulated process, but in tumors, the process can become disorganized. In prostate cancer, both increased vessel density 65 and vessel morphology 76 have been shown to be associated with prognostic implications. In addition, tumor vascular endothelial growth factor (VEGF) expression has been associated with poor prognosis in those receiving both surgery and radiation as primary treatment.
Tissue Invasion and Metastasis
Prostate cancerYspecific mortality is typically the result of distant spread of the tumor. The processes controlling this capacity to invade and ultimately metastasize are not fully understood, but the tumor microenvironment is thought to play a crucial role. Markers of cell adhesion such as E-cadherin and cytokines such a transforming growth factor A (TGF-A) have prognostic significance following surgery in prostate cancer as outlined in Table 1 and in the following sections.
Molecular Signatures
Rather than focusing on individual markers, ''molecular signatures'' represent the use of multiple markers that together attempt to provide prognostic markers of prostate cancer progression. Several groups have reported on molecular signatures derived from prostate tumors, although many have been based on small study populations. Moreover, few have identified robust signatures that validate across different prostate cancer cohorts. For a molecular signature to be useful clinically, the set of markers should be predictive of prostate cancer outcomes independent of Gleason grade and other clinical markers. In the following sections, we summarize the results from 3 promising signatures of prostate cancer recurrence and/or death.
Molecular Signature of Copy Number Alterations
Taylor et al 77 undertook an integrative genomic analysis of the tumors of 218 prostate cancer patients followed up for a median of 5 years for biochemical recurrence. The tumors were annotated molecularly using whole-genome mRNA, miRNA, and copy number aberrations platforms. Using an unsupervised hierarchical clustering, the authors were unable to identify a signature at the mRNA or miRNA levels that could distinguish men who did or did not have a recurrence. However, there was a distinct signature within the copy number data that predicted differences in time to biochemical relapse, independent of Gleason grade. An important future direction with this signature is to test its prognostic ability within a cohort using lethal prostate cancer as the endpoint.
Cell-Cycle Progression Signature
Rather than a discovery-based approach, Cuzick et al 74 used a pathway-based approach, focusing on genes involved in 
Marker Action Notes
Self-sufficiency in growth signals Androgen receptor Acts as a transcription factor mediating cell growth Heterogeneous data based on immunohistochemistry but large radical prostatectomy series appear to support its prognostic value. 40 Mutations are common in the castration-resistant setting and are associated with response. 41 
Ki-67
Nuclear antigen denoting cellular proliferation
Ki-67 has been found to be prognostic in radiation-treated patients 42 as well as those undergoing radical prostatectomy 43 TMPRSS2:ERG Gene fusion between androgen-responsive element and a family of transcription factors
Present in approximately 50% of localized prostate cancers, this gene fusion has been associated with lethal disease in watchful waiting cohorts 44, 45 but in contrast was not associated with outcomes in other radical prostatectomy series. 46 Currently, the balance of the growing literature is that this marker holds no prognostic significance following prostatectomy.
AKT/PTEN Components of the phosphoinositol 3-kinase oncogenic pathway
Loss of the tumor suppressor gene PTEN is related to clinical outcomes in radical prostatectomy specimens. 47, 48 Similarly, the presence of the activated form of AKT 49 The FASN gene is implicated as an oncogene in prostate cancer 53 and has independent prognostic value following prostatectomy 54 EZH2
Gene-silencing protein High expression of EZH2 is associated with a poor prognosis in localized disease and is present in metastatic disease 55 Insensitivity to antigrowth signals p16/INK4A Tumor suppressor gene related to cell cycle control Overexpression of p16/INK4A is independently related to recurrence of disease 56 P21/WAF1/CIP1
Regulates G 1 of the cell cycle Increased p21/WAF1/CIP1 staining is independently prognostic for recurrent disease following prostatectomy 57 P27/KIP1
Cell cycle inhibitor Decreased expression of the protein is independently associated with poor outcomes. 47, 58 The protein SKP2 targets p27/KIP1 for degradation and higher levels also correlate with worsened outcome 59 C-MYC Oncogenic transcription factor Fluorescence in situ hybridization copy number for the gene significantly predicts progression and survival, 60 although with immunohistochemistry, expression of C-MYC is not independently related to clinical outcome. 61 In the postprostatectomy setting, nuclear p53 expression is independently associated with disease progression 64 BCL2
Apoptosis regulator Increased nuclear expression of BCL2 is independently prognostic for recurrence following radical prostatectomy. 65, 66 Similar results were found on biopsy specimens from patients receiving radiation 67 
BAX
Proapoptotic member of the BCL2 family
The ratio of BCL2: BAX was predictive of worsened outcome following radiation 68 Sustained angiogenesis VEGF Driver of neovascularization Among patients receiving radiation 69 and surgery, 70 VEGF staining predicted shorter time to biochemical recurrence Tissue invasion and metastasis E-cadherin Cell adhesion molecule Low expression of E-cadherin is independently associated with death in men treated with transurethral resection of prostate 71 
TGF-A
Progrowth cytokine TGF-A is implicated as a key factor in the tumor microenvironement of prostate cancers, and increased tumor expression is associated with metastases and poor prognosis 72, 73 cell-cycle progression defined as genes whose expression varied as a function of the cell cycle. Interestingly, genes involved in cell-cycle progression have been informative prognostic markers in other cancers including breast. 78 Through curation of the Gene Expression Omnibus database, the researchers identified 126 genes involved in cell cycle regulation. They measured mRNA levels of the genes in a small cohort to examine intergene correlations and further reduced the set to 31 genes based on high correlation to mean expression with the idea that these would provide a robust measure of cell proliferation. In a prostatectomy cohort of 366 prostate cancer patients, mRNA expression of genes in the cell-cycle progression signature predicted biochemical recurrence, independent of Gleason and other clinical factors. Moreover, in a cohort of 337 men with prostate cancer diagnosed on transurethral resection of prostate, the signature predicted lethal prostate cancer, independent of Gleason grade and Ki-67 expression.
Four-Marker Signature of Lethal Prostate Cancer
Ding et al 72 used comparative oncogenomics to derive a signature of prostate cancer prognosis. Investigating the noninvasive prostatic intraepithelial neoplasia that develops in Pten-null mice, they found significant up-regulation of TGF-A/ Smad4 among other pathways. The group then observed that in a mouse engineered to have loss of both Pten and Smad4 within the prostate, metastatic prostate cancer developed. Comparing mRNA expression profiles of tumors from this homogeneous genetic background to the lesions that develop in mice without prostatic Pten showed alterations in several pathways associated with progression in human tumors. These genes were enlisted into functional assays for proliferation and invasion and, in some cases, metastasis. Combining these analyses with the direct targets of Smad4 yielded cyclin D1 and osteopontin as potential prognostic markers. High expression of CCND1 and SPP1 with loss of SMAD4 and PTEN was investigated as a signature of poor prognosis in prostate cancer. At the mRNA level, the signature was significantly associated with biochemical recurrence and lethal prostate cancer in 2 small cohorts. Moreover, protein expression of the 4 markers was assessed in a cohort of 367 prostate cancers from men in the Physicians' Health Study who had undergone radical prostatectomy. The 4-marker signature was a significantly better predictor of lethal prostate cancer than Gleason score alone and when combined with age and tumor stage produced a C-statistic of 0.91 (95% confidence interval, 0.86Y0.96). These 4 markers are currently undergoing independent validation in another large cohort of samples annotated with cancer-specific deaths.
Signature of Gleason Score
Given the proven importance of the Gleason score in prediction clinical course, Penney et al 79 developed a 157-gene mRNA expression signature associated with Gleason grade. To develop the signature, tumors composed of Gleason 3+3 and Gleason 8 or greater were compared. When the signature was applied to Gleason 7 tumors, an increased probability of being high grade was associated with a significantly increased risk of lethal prostate cancer. For each 33% increase in the prediction of high-grade tumor, there was an odds ratio of 1.47 (95% confidence interval, 1.11Y1.94) for lethal outcome in a multivariate model. These 4 signatures hold promise to improve prognostication among men diagnosed with prostate cancer. Important next steps in bringing forward these signatures clinically is the validation in additional cohorts with lethal prostate cancer as the endpoint, determining potential weighting of the individual markers for optimization, as well as the testing of the signatures in biopsy specimens.
Circulating Biomarkers
Although tumor markers are appealing in that they may represent true biological changes within the cells of interest, investigators have also explored other sources for prognostic markers in prostate cancer. Blood or urine markers are attractive potential prognostic markers not only for their ease of access but also because they may overcome concerns of the sampling errors and heterogeneity from the tumor itself.
Circulating Tumor Cells
The development of overt metastases has been typically considered a late event in the malignant progression, but there is evolving evidence that suggests that dissemination of primary cancer cells to distant sites might occur early in tumorigenesis. 80 The bone represents the most common location of metastatic disease in prostate cancer, and therefore early work on circulating tumor cells focused on tumor cells in the bone marrow. There are significant correlations between the presence of disseminated tumor cells and clinical-pathological parameters such as high Gleason score or metastatic disease. 81, 82 The presence of these cells in the bone marrow at the time of diagnosis is also an independent negative prognostic parameter in patients with localized prostate cancer. 83 Because bone marrow aspiration is invasive and potentially uncomfortable for the patients, more recent efforts have focused on the detection of circulating tumor cells in the peripheral blood. Using polymerase chain reaction, circulating tumor cells can now be detected in the blood at the time of diagnosis as well as over the course of therapy. Their increased number has been positively associated with higher Gleason score and stage. 84 The detection of PSA mRNA is significantly correlated to time to progression and overall survival. 85 Immunologic approaches to detecting circulating tumor cells have subsequently been commercially developed. The Food and Drug Administration has approved a technology (Cell-Search; Veridex, Raritan, NJ) that can be used for the monitoring of metastatic breast, colon, and prostate cancer. With recently collected peripheral blood, this device is able to isolate single circulating tumor cells by immunomagnetic enrichment followed by fluorometric count. Data generated using this system show that circulating tumor cells are detectable in approximately 60% of patients with androgen-independent prostate cancer. 86, 87 A baseline count of 5 cells/7.5 mL of blood or greater before therapy was found to represent a powerful predictor of poor overall survival. 88 The change in number of detectable circulating tumor cells following therapy is also predictive of clinical outcomes. 85 In a study, patients with a circulating tumor cell count that dropped from 5 cells or greater at baseline to less than 5 cells after treatment had a better overall survival compared with those showing an increase during therapy. 89 Although potentially valuable in the metastatic setting, in patients with organ-confined prostate cancer, few circulating tumor cells are detectable using available technologies and do not correlate with known prognostic factors. 90 In addition to their potential prognostic value, there is clearly likely utility in characterizing circulating tumor cells in cancer patients to provide additional information on cancer biology and treatment selection. Newer microfluidic approaches of capturing circulating tumor cells are being commercially developed. 91, 92 Both high-and low-resolution techniques such as fluorescence in situ hybridization and comparative genomic hybridization can be performed on isolated cancer cells to obtain a genomic profile that could be related to prognosis and response to therapy. 93Y95 In non-small cell lung cancer, a proof-of-concept study showed that circulating tumor cells could identify tumors with specific EGFR mutations sensitive to anti-EGFR small molecules demonstrating the value of these ''liquid biopsies.'' 96
Urine Markers
Given the proximity of the urethra to the prostate, urine is also considered a potential source of clinically useful biomarkers in men with prostate cancer. The prostate cancer antigen 3 (PCA3) gene is differentially expressed in prostate cancer samples compared with normal prostate tissue. 97 The protein product can be identified in urine, particularly in the first void after a digital rectal examination when tumor cells are known to be present. 98, 99 To date, much of the work with PCA3 has been limited to the diagnosis of men with prostate cancer. In this setting, it has been shown that PCA3 can improve upon the specificity of PSA. 100 One study also showed that PCA3 was independently correlated with extracapsular extension identified on radical prostatectomy. 101 The TMPRSS2:ERG fusion has also been investigated in the urine. 102, 103 Its presence can be detected in postYdigital rectal examination urine, and its presence may eventually be used in combination with other biomarkers to improve the specificity of screening for prostate cancer. 104, 105 Profiling the metabolites from normal and prostate cancer cells, Sreekumar et al 106 showed that the presence of sarcosine was related to prostate cancer progression and that the level of this metabolite in the urine was associated with the presence of cancer. Whether sarcosine or other metabolites will prove useful as prognostic markers in prostate cancer is yet to be determined.
Serum Markers
Multiple serum markers other than PSA have been investigated for their potential role in providing prognostic information in prostate cancer. Members of the human kallikrein gene family, which include PSA, have been investigated with mixed results. 107, 108 Given its proven role in the tumor microenvironment, TGF-A has also been explored in the serum as a prognostic factor. 109 Another marker believed to come from the tumor microenvironment is interleukin 6, and levels of its soluble receptor in the blood have been shown to be prognostic following radical prostatectomy. 110 
CONCLUSIONS
As outlined in this review, molecular markers of prognosis in prostate cancer are plentiful in the literature and to date have largely focused on individual factors. Despite a wide array of potential markers, they remain, to a large extent, unused clinically. This is likely the result of numerous factors including relatively modest effect size for any given marker and poor standardization of the tools of detection and analysis: from antibody selection to biomarker interpretation to selecting cutpoints for ''positive'' and ''negative,'' there is significant room for variability. This variability leads frequently to poor reproducibility between studies and difficulty in interpreting negative results. To improve the interpretability of molecular markers, there are now standardized reporting criteria that are used by some journals for biomarker studies. 111 The widespread adoption of these recommendations will help overcome some of these methodological issues. Technologic advances in biomarker assessment such as multispectral imaging 112 may also prove useful as multiple markers may be needed simultaneously to best predict the clinical course.
More recent studies have focused on the identification and validation of molecular signatures, and these appear to hold great promise as prognostic markers in prostate cancer. Approaches looking specifically at Gleason grade 79 and cell-cycle progression 74 highlight that analyses focused on capturing the biology of prostate cancer may prove very useful in individualizing therapy for men. Furthermore, comparative oncogenomics with functional validation of the drivers of a biological process 72 have helped to overcome the significant heterogeneity seen in human prostate cancer to provide critical insights into the prognosis of a man following surgery or possibly at the time of diagnosis. These signatures will need further validation and ultimately trials to foster widespread adoption, but we appear to be increasingly close to a time when a man can be given a much more reliable prognosis when he is diagnosed with prostate cancer.
